

Panitumumab PRIME

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Panitumumab PRIME

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: First-line treatment of patients with wild-type RAS mCRC

Experimental Arm: Panitumumab + FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)

Control Arm: FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)

